{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:34:16Z","timestamp":1788910456803,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"crossref","award":["DST\/INSPIRE\/03\/2016\/000026"],"award-info":[{"award-number":["DST\/INSPIRE\/03\/2016\/000026"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"crossref","award":["DBT\/2021\u201322\/CBR\/1593"],"award-info":[{"award-number":["DBT\/2021\u201322\/CBR\/1593"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"crossref","award":["BT\/PR40153\/BTIS\/137\/8\/2021"],"award-info":[{"award-number":["BT\/PR40153\/BTIS\/137\/8\/2021"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dr. B. R. Ambedkar Center for Biomedical Research and the Institute of Eminence, University of Delhi","award":["IoE\/2023-24\/12\/FRP"],"award-info":[{"award-number":["IoE\/2023-24\/12\/FRP"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-78330-5","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T02:59:04Z","timestamp":1731639544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Identification of novel PAD2 inhibitors using pharmacophore-based virtual screening, molecular docking, and MD simulation studies"],"prefix":"10.1038","volume":"14","author":[{"given":"Prakash","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Rajoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Poonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"78330_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0005-2795(77)90250-1","volume":"495","author":"GE Rogers","year":"1977","unstructured":"Rogers, G. E., Harding, H. W. J. & Llewellyn-Smith, I. J. The origin of citrulline-containing proteins in the hair follicle and the chemical nature of trichohyalin, an intracellular precursor. Biochim. Biophys. Acta BBA Protein Struct. 495, 159\u2013175 (1977).","journal-title":"Biochim. Biophys. Acta BBA Protein Struct."},{"key":"78330_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/182186a0","volume":"182","author":"GE Rogers","year":"1958","unstructured":"Rogers, G. E. & Simmonds, D. H. Content of citrulline and other amino-acids in a protein of hair follicles. Nature 182, 186\u2013187 (1958).","journal-title":"Nature"},{"key":"78330_CR3","doi-asserted-by":"publisher","first-page":"134576","DOI":"10.1016\/j.ijbiomac.2024.134576","volume":"278","author":"P Mansouri","year":"2024","unstructured":"Mansouri, P. et al. Peptidylarginine deiminase (PAD): A promising target for chronic diseases treatment. Int. J. Biol. Macromol. 278, 134576 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"78330_CR4","doi-asserted-by":"publisher","first-page":"1487742","DOI":"10.1080\/20002297.2018.1487742","volume":"10","author":"I Olsen","year":"2018","unstructured":"Olsen, I., Singhrao, S. K. & Potempa, J. Citrullination as a plausible link to periodontitis, rheumatoid arthritis, atherosclerosis and Alzheimer\u2019s disease. J. Oral Microbiol. 10, 1487742 (2018).","journal-title":"J. Oral Microbiol."},{"key":"78330_CR5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1158\/0008-5472.CAN-18-2797","volume":"79","author":"AE Yuzhalin","year":"2019","unstructured":"Yuzhalin, A. E. Citrullination in cancer. Cancer Res. 79, 1274\u20131284 (2019).","journal-title":"Cancer Res."},{"key":"78330_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1046\/j.1432-1327.1999.00083.x","volume":"259","author":"AA Rus\u2019d","year":"1999","unstructured":"Rus\u2019d, A. A. et al. Molecular cloning of cDNAs of mouse peptidylarginine deiminase type I, type III and type IV, and the expression pattern of type I in mouse. Eur. J. Biochem. 259, 660\u2013669 (1999).","journal-title":"Eur. J. Biochem."},{"key":"78330_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0003-9861(02)00516-7","volume":"407","author":"A Ishigami","year":"2002","unstructured":"Ishigami, A. et al. Human peptidylarginine deiminase type II: Molecular cloning, gene organization, and expression in human skin. Arch. Biochem. Biophys. 407, 25\u201331 (2002).","journal-title":"Arch. Biochem. Biophys."},{"key":"78330_CR8","doi-asserted-by":"crossref","unstructured":"Chavanas, S. et al. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6. Gene 330, 19\u201327 (2004).","DOI":"10.1016\/j.gene.2003.12.038"},{"key":"78330_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000518414","volume":"89","author":"M Gijon","year":"2022","unstructured":"Gijon, M., Metheringham, R. L., Toss, M. S., Paston, S. J. & Durrant, L. G. The clinical and prognostic significance of protein arginine deiminases 2 and 4 in colorectal cancer. Pathobiology 89, 38\u201348 (2022).","journal-title":"Pathobiology"},{"key":"78330_CR10","doi-asserted-by":"publisher","first-page":"188931","DOI":"10.1016\/j.bbcan.2023.188931","volume":"1878","author":"Y Teng","year":"2023","unstructured":"Teng, Y., Chen, Y., Tang, X., Wang, S. & Yin, K. PAD2: A potential target for tumor therapy. Biochim. Biophys. Acta Rev. Cancer 1878, 188931 (2023).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"78330_CR11","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1021\/cb500933j","volume":"10","author":"DJ Slade","year":"2015","unstructured":"Slade, D. J. et al. Protein arginine deiminase 2 binds calcium in an ordered fashion: Implications for inhibitor design. ACS Chem. Biol. 10, 1043\u20131053 (2015).","journal-title":"ACS Chem. Biol."},{"key":"78330_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2008.09.009","volume":"53","author":"S Ying","year":"2009","unstructured":"Ying, S. et al. Transcriptional regulation of peptidylarginine deiminase expression in human keratinocytes. J. Dermatol. Sci. 53, 2\u20139 (2009).","journal-title":"J. Dermatol. Sci."},{"key":"78330_CR13","doi-asserted-by":"publisher","first-page":"188492","DOI":"10.1016\/j.bbcan.2020.188492","volume":"1875","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. PADs in cancer: Current and future. Biochim. Biophys. Acta Rev. Cancer 1875, 188492 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"78330_CR14","doi-asserted-by":"crossref","unstructured":"Cherrington, B. D. et al. Potential role for PAD2 in gene regulation in breast cancer cells. PLoS ONE 7, (2012).","DOI":"10.1371\/journal.pone.0041242"},{"key":"78330_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0304-4165(88)90088-8","volume":"966","author":"K Watanabe","year":"1988","unstructured":"Watanabe, K. et al. Combined biochemical and immunochemical comparison of peptidylarginine deiminases present in various tissues. Biochim. Biophys. Acta 966, 375\u2013383 (1988).","journal-title":"Biochim. Biophys. Acta"},{"key":"78330_CR16","doi-asserted-by":"publisher","first-page":"13331","DOI":"10.1073\/pnas.1203280109","volume":"109","author":"X Zhang","year":"2012","unstructured":"Zhang, X. et al. Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor \u03b1 target gene activation. Proc. Natl. Acad. Sci. 109, 13331\u201313336 (2012).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"78330_CR17","doi-asserted-by":"publisher","first-page":"e1006848","DOI":"10.1371\/journal.pgen.1006848","volume":"13","author":"M Khajavi","year":"2017","unstructured":"Khajavi, M. et al. Identification of Padi2 as a novel angiogenesis-regulating gene by genome association studies in mice. PLoS Genet. 13, e1006848 (2017).","journal-title":"PLoS Genet."},{"key":"78330_CR18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/1471-2407-12-500","volume":"12","author":"JL McElwee","year":"2012","unstructured":"McElwee, J. L. et al. Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer 12, 500 (2012).","journal-title":"BMC Cancer"},{"key":"78330_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12935-016-0335-0","volume":"16","author":"H Wang","year":"2016","unstructured":"Wang, H. et al. PADI2 gene confers susceptibility to breast cancer and plays tumorigenic role via ACSL4, BINC3 and CA9 signaling. Cancer Cell. Int. 16, 61 (2016).","journal-title":"Cancer Cell. Int."},{"key":"78330_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12885-017-3354-x","volume":"17","author":"S Horibata","year":"2017","unstructured":"Horibata, S. et al. Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration. BMC Cancer 17, 378 (2017).","journal-title":"BMC Cancer"},{"key":"78330_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s13046-019-1404-8","volume":"38","author":"F Li","year":"2019","unstructured":"Li, F. et al. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells. J. Exp. Clin. Cancer Res. 38, 414 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"78330_CR22","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/0008-5472.CAN-17-0150","volume":"77","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. PADI2-Mediated citrullination promotes prostate cancer progression. Cancer Res. 77, 5755\u20135768 (2017).","journal-title":"Cancer Res."},{"key":"78330_CR23","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1002\/cam4.3013","volume":"9","author":"ME Urick","year":"2020","unstructured":"Urick, M. E. & Bell, D. W. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target. Cancer Med. 9, 3863\u20133874 (2020).","journal-title":"Cancer Med."},{"key":"78330_CR24","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2174\/1871525717666190717162646","volume":"19","author":"M Asad","year":"2019","unstructured":"Asad, M., Wajid, S., Katare, D. P., Mani, R. J. & Jain, S. K. Differential expression of TOM34, AL1A1, PADI2 and KLRBA in NNK induced lung cancer in wistar rats and their implications. Curr. Cancer Drug Targets 19, 919\u2013929 (2019).","journal-title":"Curr. Cancer Drug Targets"},{"key":"78330_CR25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1021\/acs.accounts.9b00024","volume":"52","author":"S Mondal","year":"2019","unstructured":"Mondal, S. & Thompson, P. R. Protein arginine deiminases (PADs): Biochemistry and chemical biology of protein citrullination. Acc. Chem. Res. 52, 818\u2013832 (2019).","journal-title":"Acc. Chem. Res."},{"key":"78330_CR26","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3390\/ijms18112258","volume":"18","author":"B Jang","year":"2017","unstructured":"Jang, B., Ishigami, A., Kim, Y. S. & Choi, E. K. The peptidylarginine deiminase inhibitor Cl-Amidine suppresses inducible nitric oxide synthase expression in dendritic cells. Int. J. Mol. Sci. 18, 2258 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"78330_CR27","doi-asserted-by":"crossref","unstructured":"Mart\u00edn Monreal, M. T. et al. Applicability of small-molecule inhibitors in the study of peptidyl arginine deiminase 2 (PAD2) and PAD4. Front. Immunol. 12, (2021).","DOI":"10.3389\/fimmu.2021.716250"},{"key":"78330_CR28","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2174\/1389450116666150202160954","volume":"16","author":"EE Witalison","year":"2015","unstructured":"Witalison, E. E., Thompson, P. R. & Hofseth, L. J. Protein arginine deiminases and associated citrullination: Physiological functions and diseases associated with dysregulation. Curr. Drug Targets 16, 700\u2013710 (2015).","journal-title":"Curr. Drug Targets"},{"key":"78330_CR29","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1021\/acs.jmedchem.7b00274","volume":"60","author":"A Muth","year":"2017","unstructured":"Muth, A. et al. Development of a selective inhibitor of protein arginine deiminase 2. J. Med. Chem. 60, 3198\u20133211 (2017).","journal-title":"J. Med. Chem."},{"issue":"Suppl 17","key":"78330_CR30","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1471-2105-13-S17-S4","volume":"13","author":"CY Teo","year":"2012","unstructured":"Teo, C. Y. et al. Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening. BMC Bioinform. 13(Suppl 17), S4 (2012).","journal-title":"BMC Bioinform."},{"key":"78330_CR31","doi-asserted-by":"crossref","unstructured":"Rahman, M. B. A. C. Y. T. Ligand-based virtual screening for the discovery of inhibitors for protein arginine deiminase type 4 (PAD4). in J. Postgenomics Drug Biomark. Dev. 03 (2013).","DOI":"10.4172\/2153-0769.1000118"},{"key":"78330_CR32","unstructured":"Syst\u00e8mes, D. BIOVIA, discovery studio visualizer, release 2019. San Diego Dassault Syst\u00e8mes (2020)."},{"key":"78330_CR33","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701\u20131718 (2005).","journal-title":"J. Comput. Chem."},{"key":"78330_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.csbj.2019.02.006","volume":"17","author":"S Pal","year":"2019","unstructured":"Pal, S. et al. Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase I inhibitors. Comput. Struct. Biotechnol. J. 17, 291\u2013310 (2019).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"78330_CR35","doi-asserted-by":"publisher","first-page":"e63030","DOI":"10.1371\/journal.pone.0063030","volume":"8","author":"M Arooj","year":"2013","unstructured":"Arooj, M., Sakkiah, S., Kim, S., Arulalapperumal, V. & Lee, K. W. A combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitors. PLoS ONE 8, e63030 (2013).","journal-title":"PLoS ONE"},{"key":"78330_CR36","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.3390\/molecules26164961","volume":"26","author":"TA Bouback","year":"2021","unstructured":"Bouback, T. A. et al. Pharmacophore-based virtual screening, quantum mechanics calculations, and molecular dynamics simulation approaches identified potential natural antiviral drug candidates against MERS-CoV S1-NTD. Molecules 26, 4961 (2021).","journal-title":"Molecules"},{"key":"78330_CR37","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1007\/s00894-011-1328-5","volume":"18","author":"W Tai","year":"2012","unstructured":"Tai, W. et al. Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors. J. Mol. Model. 18, 3087\u20133100 (2012).","journal-title":"J. Mol. Model."},{"key":"78330_CR38","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","volume":"55","author":"T Sterling","year":"2015","unstructured":"Sterling, T. & Irwin, J. J. ZINC 15\u2013ligand discovery for everyone. J. Chem. Inf. Model. 55, 2324\u20132337 (2015).","journal-title":"J. Chem. Inf. Model."},{"key":"78330_CR39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.drudis.2018.10.016","volume":"24","author":"DM Volochnyuk","year":"2019","unstructured":"Volochnyuk, D. M. et al. Evolution of commercially available compounds for HTS. Drug Discov Today 24, 390\u2013402 (2019).","journal-title":"Drug Discov Today"},{"key":"78330_CR40","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1016\/j.ddtec.2010.11.004","volume":"7","author":"T Seidel","year":"2010","unstructured":"Seidel, T., Ibis, G., Bendix, F. & Wolber, G. Strategies for 3D pharmacophore-based virtual screening. Drug Discov Today Technol. 7, e221\u2013e228 (2010).","journal-title":"Drug Discov Today Technol."},{"key":"78330_CR41","doi-asserted-by":"publisher","first-page":"e07666","DOI":"10.1016\/j.heliyon.2021.e07666","volume":"7","author":"CN Hiremath","year":"2021","unstructured":"Hiremath, C. N. Abbreviated Profile of drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatments. Heliyon 7, e07666 (2021).","journal-title":"Heliyon"},{"key":"78330_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2022.2079561","volume":"0","author":"P Jha","year":"2022","unstructured":"Jha, P., Saluja, D. & Chopra, M. Structure-guided pharmacophore based virtual screening, docking, and molecular dynamics to discover repurposed drugs as novel inhibitors against endoribonuclease Nsp15 of SARS-CoV-2. J. Biomol. Struct. Dyn. 0, 1\u201311 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"78330_CR43","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1021\/ci6004299","volume":"47","author":"SN Rao","year":"2007","unstructured":"Rao, S. N., Head, M. S., Kulkarni, A. & LaLonde, J. M. Validation studies of the site-directed docking program LibDock. J. Chem. Inf. Model. 47, 2159\u20132171 (2007).","journal-title":"J. Chem. Inf. Model."},{"key":"78330_CR44","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/jcc.10306","volume":"24","author":"G Wu","year":"2003","unstructured":"Wu, G., Robertson, D. H., Brooks, I. I. I., Vieth, M. & C. L. & Detailed analysis of grid-based molecular docking: A case study of CDOCKER\u2014A CHARMm-based MD docking algorithm. J. Comput. Chem. 24, 1549\u20131562 (2003).","journal-title":"J. Comput. Chem."},{"key":"78330_CR45","doi-asserted-by":"publisher","first-page":"115699","DOI":"10.1016\/j.molliq.2021.115699","volume":"330","author":"MA Alamri","year":"2021","unstructured":"Alamri, M. A. et al. Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation. J. Mol. Liq. 330, 115699 (2021).","journal-title":"J. Mol. Liq."},{"key":"78330_CR46","doi-asserted-by":"publisher","first-page":"105710","DOI":"10.1016\/j.bioorg.2022.105710","volume":"122","author":"A Hamdi","year":"2022","unstructured":"Hamdi, A. et al. Design, synthesis, antitumor, and VEGFR-2 inhibition activities of novel 4-anilino-2-vinyl-quinazolines: Molecular modeling studies. Bioorg. Chem. 122, 105710 (2022).","journal-title":"Bioorg. Chem."},{"key":"78330_CR47","unstructured":"Software. https:\/\/www.cresset-group.com\/software\/"},{"key":"78330_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"78330_CR49","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/jcc.1078","volume":"22","author":"LD Schuler","year":"2001","unstructured":"Schuler, L. D., Daura, X. & van Gunsteren, W. F. An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase. J. Comput. Chem. 22, 1205\u20131218 (2001).","journal-title":"J. Comput. Chem."},{"key":"78330_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00214-009-0590-4","volume":"125","author":"M Fuhrmans","year":"2010","unstructured":"Fuhrmans, M., Sanders, B. P., Marrink, S. J. & de Vries, A. H. Effects of bundling on the properties of the SPC water model. Theor. Chem. Acc. 125, 335\u2013344 (2010).","journal-title":"Theor. Chem. Acc."},{"key":"78330_CR51","doi-asserted-by":"publisher","first-page":"054112","DOI":"10.1063\/5.0040966","volume":"154","author":"AC Simmonett","year":"2021","unstructured":"Simmonett, A. C. & Brooks, B. R. A compression strategy for particle mesh Ewald theory. J. Chem. Phys. 154, 054112 (2021).","journal-title":"J. Chem. Phys."},{"key":"78330_CR52","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 10, 449\u2013461 (2015).","journal-title":"Expert Opin. Drug Discov."},{"key":"78330_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-62703-658-0_11","volume":"1084","author":"CC David","year":"2014","unstructured":"David, C. C. & Jacobs, D. J. Principal component analysis: A method for determining the essential dynamics of proteins. Methods Mol. Biol. Clifton NJ 1084, 193\u2013226 (2014).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"78330_CR54","doi-asserted-by":"publisher","first-page":"109380","DOI":"10.1016\/j.abb.2022.109380","volume":"729","author":"Z Shafiee","year":"2022","unstructured":"Shafiee, Z. et al. Insights into the molecular mechanism of triazolopyrimidinone derivatives effects on the modulation of \u03b11\u03b22\u03b32 subtype of GABAA receptor: An in silico approach. Arch. Biochem. Biophys. 729, 109380 (2022).","journal-title":"Arch. Biochem. Biophys."},{"key":"78330_CR55","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/17460441.2019.1588883","volume":"14","author":"J Konc","year":"2019","unstructured":"Konc, J. Binding site comparisons for target-centered drug discovery. Expert Opin. Drug Discov. 14, 445\u2013454 (2019).","journal-title":"Expert Opin. Drug Discov."},{"key":"78330_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6026\/97320630012149","volume":"12","author":"ST Baby","year":"2016","unstructured":"Baby, S. T., Sharma, S., Enaganti, S. & Cherian, P. R. Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) inhibitors. Bioinformation 12, 149\u2013155 (2016).","journal-title":"Bioinformation"},{"key":"78330_CR57","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00894-008-0350-8","volume":"14","author":"M Chopra","year":"2008","unstructured":"Chopra, M., Gupta, R., Gupta, S. & Saluja, D. Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using Catalyst. J. Mol. Model. 14, 1087\u20131099 (2008).","journal-title":"J. Mol. Model."},{"key":"78330_CR58","doi-asserted-by":"crossref","unstructured":"R\u00e9au, M., Langenfeld, F., Zagury, J. F., Lagarde, N. & Montes, M. Decoys selection in benchmarking datasets: Overview and perspectives. Front. Pharmacol. 9, (2018).","DOI":"10.3389\/fphar.2018.00011"},{"key":"78330_CR59","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/ci800293n","volume":"49","author":"KE Hevener","year":"2009","unstructured":"Hevener, K. E. et al. Validation of molecular docking programs for virtual screening against dihydropteroate synthase. J. Chem. Inf. Model. 49, 444\u2013460 (2009).","journal-title":"J. Chem. Inf. Model."},{"key":"78330_CR60","first-page":"559","volume":"11","author":"U Rester","year":"2008","unstructured":"Rester, U. From virtuality to reality - virtual screening in lead discovery and lead optimization: A medicinal chemistry perspective. Curr. Opin. Drug Discov. Devel. 11, 559\u2013568 (2008).","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"78330_CR61","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/med.10041","volume":"23","author":"I Muegge","year":"2003","unstructured":"Muegge, I. Selection criteria for drug-like compounds. Med. Res. Rev. 23, 302\u2013321 (2003).","journal-title":"Med. Res. Rev."},{"key":"78330_CR62","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","volume":"7","author":"XY Meng","year":"2011","unstructured":"Meng, X. Y., Zhang, H. X., Mezei, M. & Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des. 7, 146\u2013157 (2011).","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"78330_CR63","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/med.21862","volume":"42","author":"G Macip","year":"2022","unstructured":"Macip, G. et al. Haste makes waste: a critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition. Med. Res. Rev. 42, 744\u2013769 (2022).","journal-title":"Med. Res. Rev."},{"key":"78330_CR64","first-page":"157","volume":"63","author":"A Andrikopoulou","year":"2022","unstructured":"Andrikopoulou, A. et al. The emerging role of capivasertib in breast cancer. Breast Off. J. Eur. Soc. Mastology. 63,157\u2013167 (2022).","journal-title":"Breast Off. J. Eur. Soc. Mastology."},{"key":"78330_CR65","first-page":"157","volume":"63","author":"D Blunt","year":"2017","unstructured":"Blunt, M. D. et al. The Dual Syk\/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and MicroenvironmentalSignaling in Chronic Lymphocytic Leukemia. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 23, 2313\u20132324 (2017).","journal-title":"Breast Off. J. Eur. Soc. Mastology."},{"key":"78330_CR66","first-page":"744","volume":"42","author":"J Holcakova","year":"2010","unstructured":"Holcakova, J. et al. The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.Antivir. Chem. Chemother. 20, 133\u2013142 (2010).","journal-title":"Med. Res. Rev."},{"key":"78330_CR67","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1021\/acs.jctc.7b00028","volume":"13","author":"K Sargsyan","year":"2017","unstructured":"Sargsyan, K., Grauffel, C. & Lim, C. How molecular size impacts RMSD applications in molecular dynamics simulations. J. Chem. Theory Comput. 13, 1518\u20131524 (2017).","journal-title":"J. Chem. Theory Comput."},{"key":"78330_CR68","doi-asserted-by":"publisher","first-page":"e0119264","DOI":"10.1371\/journal.pone.0119264","volume":"10","author":"L Mart\u00ednez","year":"2015","unstructured":"Mart\u00ednez, L. Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis. PLoS ONE 10, e0119264 (2015).","journal-title":"PLoS ONE"},{"key":"78330_CR69","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.sbi.2007.12.007","volume":"18","author":"WF van Gunsteren","year":"2008","unstructured":"van Gunsteren, W. F., Dolenc, J. & Mark, A. E. Molecular simulation as an aid to experimentalists. Curr. Opin. Struct. Biol. 18, 149\u2013153 (2008).","journal-title":"Curr. Opin. Struct. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78330-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T05:02:37Z","timestamp":1731646957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78330-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78330"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78330-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28097"}}